Roche gets USFDA nod for combo drug Venclexta, Gazyva to treat lymphocytic leukaemia Medical Dialogues Bureau17 May 2019 9:15 AM IST"Venclexta plus Gazyva is the only chemotherapy-free option of fixed duration that provides durable responses to help people live longer without...
Novartis division Alcon spinoff ousts Baer from Swiss benchmark SMI Medical Dialogues Bureau5 April 2019 9:00 AM ISTNovartis has estimated Alcon's value at around 25 billion Swiss francs ($25 billion), while some analysts predict an initial market capitalisation of...
Novartis to pay $310 million for assets from inflammation specialist IFM Garima2 April 2019 9:00 AM ISTIFM, whose research head Martin Seidel spent more than a decade at Novartis before assuming R&D duties at IFM in 2017, focuses on immune system...
Novartis Kymriah wins UK backing after initial lymphoma snub Medical Dialogues Bureau3 Feb 2019 10:00 AM IST"Today's positive announcement regarding access to Kymriah treatment in England and Wales was secured as a result of our close working collaboration...
Novartis Aimovig not cost effective: UK price watchdog Medical Dialogues Bureau11 Jan 2019 9:00 AM ISTNovartis, whose U.K. price for Aimovig is about 5,000 pounds ($6,374) annually but which was offering discounts, is counting on the medicine to be a...
Novartis to buy France's CellforCure to boost cell, gene therapy Medical Dialogues Bureau24 Dec 2018 9:00 AM ISTNovartis, which already has an agreement with CellforCure to help make Kymriah, said it aims to add CellforCure's facilities to a similar factory in...
